These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8084203)

  • 1. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans.
    Azuma I; Otani T
    Med Res Rev; 1994 Jul; 14(4):401-14. PubMed ID: 8084203
    [No Abstract]   [Full Text] [Related]  

  • 2. Review: inducer of cytokines in vivo: overview of field and romurtide experience.
    Azuma I
    Int J Immunopharmacol; 1992 Apr; 14(3):487-96. PubMed ID: 1618600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
    Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
    Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral application of romurtide, a synthetic muramyl dipeptide derivative, stimulates nonspecific resistance to microbial infections and hematopoiesis in mice.
    Namba K; Nakajima R; Otani T; Azuma I
    Vaccine; 1996 Aug; 14(12):1149-53. PubMed ID: 8911012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of the cytokine inducer romurtide: experimental studies and clinical application.
    Azuma I
    Trends Pharmacol Sci; 1992 Dec; 13(12):425-8. PubMed ID: 1293866
    [No Abstract]   [Full Text] [Related]  

  • 6. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
    Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
    Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Theoretical problems of use of an immunomodulator likopid in clinical practice].
    Andronova TM; Chumakova MM
    Ter Arkh; 2002; 74(1):70-2. PubMed ID: 11878067
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
    Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
    Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide.
    Suzuki K; Torii K; Hida S; Hayashi H; Hiyama Y; Oomoto Y; Takii T; Chiba T; Onozaki K
    Immunopharmacology; 1994; 28(1):31-8. PubMed ID: 7928300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
    Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
    Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrapleural therapy with MDP-Lys (L18), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer.
    Yanagawa H; Haku T; Takeuchi E; Suzuki Y; Nokihara H; Sone S
    Lung Cancer; 2000 Feb; 27(2):67-73. PubMed ID: 10688489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation of non-specific resistance to infection by muroctasin.
    Otani T; Une T; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
    Nagao S; Sato K; Osada Y
    Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restorative effect of MDP-Lys (L18) on leukopenia of cancer patient treated with radiotherapy.
    Okawa T; Kikuchi Y; Watarai J; Dokiya T; Tanaka T; Saito Y; Hirokawa Y; Takegawa Y; Hata K
    Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Apr; 48(4):514-22. PubMed ID: 3231516
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections.
    Osada Y; Mitsuyama M; Une T; Matsumoto K; Otani T; Satoh M; Ogawa H; Nomoto K
    Infect Immun; 1982 Jul; 37(1):292-300. PubMed ID: 6809630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
    Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM
    Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604
    [No Abstract]   [Full Text] [Related]  

  • 18. Restorative activity of muroctasin on leukopenia associated with anticancer treatment.
    Tsubura E; Nomura T; Niitani H; Osamura S; Okawa T; Tanaka M; Ota K; Nishikawa H; Masaoka T; Fukuoka M
    Arzneimittelforschung; 1988 Jul; 38(7A):1070-4. PubMed ID: 3190800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
    Akasaki M; Takashi T; Kita Y; Tsukada W
    Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.